NBI-74330 is a selective CXCR4 antagonist primarily utilized in research settings to study its effects on chemokine receptors, particularly CXCR4. It is often employed in biochemical assays and pharmacological studies to understand its potential as a therapeutic agent, especially in conditions involving cancer metastasis, HIV infection, inflammation, and autoimmune diseases. Researchers use it to explore its ability to modulate immune responses, inhibit viral entry, and reduce tumor cell migration, which could lead to insights into treating disorders like multiple myeloma, rheumatoid arthritis, multiple sclerosis, and other inflammatory conditions. Its application in preclinical and clinical studies helps in evaluating its efficacy and safety profile, paving the way for potential drug development as an anti-cancer and anti-viral agent.